



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



N1-Methylpseudouridine

Cat. No.:	HY-112582
CAS No.:	13860-38-3
Molecular Formula:	C ₁₀ H ₁₄ N ₂ O ₆
Molecular Weight:	258.23
Target:	Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis
Pathway:	Cell Cycle/DNA Damage
Storage:	<div> <div>Powder</div> <div> -20°C 3 years 4°C 2 years </div> </div> <div> <div>In solvent</div> <div> -80°C 2 years -20°C 1 year </div> </div>



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (387.25 mM; Need ultrasonic)
H₂O : 50 mg/mL (193.63 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.8725 mL	19.3626 mL	38.7252 mL
	5 mM		0.7745 mL	3.8725 mL	7.7450 mL
	10 mM		0.3873 mL	1.9363 mL	3.8725 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 50 mg/mL (193.63 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

N1-methyl-pseudouridine (1-Methylpseudouridine), a methylpseudouridine, outperforms 5 mC and 5 mC/N1-methyl-pseudouridine in translation. N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density^[1].

In Vitro	<p>Incorporation of N1-methyl-pseudouridine into mRNA modifies mRNAs produced higher amounts of luc than the standard Luc mRNA in HEK293T cells. Incorporation of N1-methyl-pseudouridine nucleoside modification in both Luc and GFP mRNA enhances the initiation step of translation, in part by suppressing eIF2α phosphorylation. In addition, polysome formation and growth on the NN1-methyl-pseudouridine-containing Luc mRNA is enhanced due to the reduction of elongation rate. In all the in vitro translation systems, incorporation of N1-methyl-pseudouridine in Luc and GFP mRNAs dramatically enhanced translation. The N1-methyl-pseudouridine-Luc mRNA is associated with heavier polysomes than Luc mRNA^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice^[2]. N1-methyl-pseudouridine (1-Methylpseudouridine) (20 μg; i.m. or i.d. routes for 21 days) and m5C/ N1-methyl-pseudouridine-modified mRNA respectively have a higher translational capacity than Ψ and m5C/Ψ-modified mRNA in vivo ^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table> <tr> <td>Animal Model:</td><td>7-week-old Balb/c mice^[1]</td></tr> <tr> <td>Dosage:</td><td>20 μg</td></tr> <tr> <td>Administration:</td><td>i.m. or i.d. routes for 21 days</td></tr> <tr> <td>Result:</td><td>had a higher translational capacity.</td></tr> </table>	Animal Model:	7-week-old Balb/c mice ^[1]	Dosage:	20 μ g	Administration:	i.m. or i.d. routes for 21 days	Result:	had a higher translational capacity.
Animal Model:	7-week-old Balb/c mice ^[1]								
Dosage:	20 μ g								
Administration:	i.m. or i.d. routes for 21 days								
Result:	had a higher translational capacity.								

REFERENCES

- [1]. Nance KD, Meier JL. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent Sci. 2021;7(5):748-756.
- [2]. Svitkin YV, et al. N1-methyl-pseudouridine in mRNA enhances translation through eIF2 α -dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res. 2017 Jun 2;45(10):6023-6036.
- [3]. Andries O, et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015 Nov 10;217:337-44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA